Cancer Research and Biotechnology AG is a Swiss preclinical oncology company focusing on metabolic diseases and mitochondrial healing for cancer treatments.
We are healing the disease that causes cancer. Our lead product corrects the root metabolic dysfunctions by restoring proper mitochondrial and cellular functions
For decades, cancer therapy has meant a painful trade-off: damage the tumour, but also the patient.
We are changing that equation.
By targeting cancer’s metabolic engine and restoring healthy mitochondrial function, we can stop cancer progression while protecting normal tissue.
The first target is Metastatic Melanoma, a very aggressive form of skin cancer.
Our drug has shown efficacy and safety on human cancer cells, and it will soon be studied in clinical trials.
